Coripharma ehf.
PolandAll drugs from this manufacturer
-
The medicine is intended for adult patients with chronic myeloid leukemia with the presence of the Philadelphia chromosome (Ph-positive type), who have newly diagnosed disease or for whom previous treatment has not been effective or appropriate.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 100 mg ATC: L01EA04
-
The medicine is intended for adult patients with chronic myeloid leukemia with the presence of the Philadelphia chromosome (Ph-positive type). It is used in cases of newly diagnosed disease or when previous medications have not yielded the expected results.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 500 mg ATC: L01EA04
-
This medicine is used in adult patients with Ph-positive chronic myeloid leukemia, who have newly diagnosed disease or for whom previous treatment has not been effective or has been inappropriate.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 100 mg ATC: L01EA04
-
The medicine is intended for adult patients with Ph-positive chronic myeloid leukemia, who have newly diagnosed disease or for whom previous treatment has been ineffective or inappropriate.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 400 mg ATC: L01EA04
-
The medicine is intended for adult patients with Ph-positive chronic myeloid leukemia. It is used in individuals whose disease has only recently been diagnosed or in those for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 500 mg ATC: L01EA04
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (who have not responded to other medicines) and in adults with hepatitis C virus infection who have a low platelet count that makes antiviral treatment difficult.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is used to treat immune thrombocytopenia in individuals over 1 year of age (when other medicines have not worked) and in adults with hepatitis C virus infection who have experienced platelet problems during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (when other medicines have not worked) and in adults with hepatitis C who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg ATC: B02BX05
-
The medicine is used for the long-term treatment of pulmonary arterial hypertension (PAH) in adults and in children weighing more than 40 kg. It helps to dilate the pulmonary arteries, which makes it easier for the heart to pump blood, lowers pressure, and reduces disease symptoms.
Dosage form: tablets, film-coated
Active substance Dosage macitentan 10 mg ATC: C02KX04
-
The medicine is used in adults to reduce the risk of another heart attack or death from cardiovascular disease (e.g., after acute coronary syndrome). It is also used to reduce the risk of blood clots in people with coronary artery disease or peripheral artery disease.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 2.5 mg ATC: B01AF01
-
The medicine is used in adults to prevent the formation of blood clots in the veins after hip or knee replacement surgery, to treat deep vein thrombosis and pulmonary embolism, and to prevent their recurrence.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 10 mg ATC: B01AF01
-
This medicine is used in adults to prevent strokes and other blood clots (e.g., in atrial fibrillation) and to treat and prevent blood clots in the leg veins and pulmonary vessels. In children and adolescents (over 30 kg), it is used to treat and prevent blood clots after initial injectable treatment.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg ATC: B01AF01
-
Rivanoptim is used in adults to prevent strokes and other blood clots (e.g., in atrial fibrillation) and to treat and prevent blood clots in the leg veins and pulmonary vessels. In children and adolescents (weighing more than 30 kg), it is used to treat blood clots after initial injectable treatment.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 20 mg ATC: B01AF01
-
The medicinal product is intended for the treatment of adults as well as children and adolescents (over 10 years of age) with relapsing-remitting multiple sclerosis.
Dosage form: tablets, film-coated
Active substance Dosage teriflunomide 14 mg ATC: L04AK02